Mentoring in Discovery and Validation of Clinical Chronic Pain Biomarkers

此K24应用程序的主要目标是允许Sean Mackey，医学博士，博士，在他的高- 在以患者为中心的研究(POR)中对职业生涯早期研究人员的高质量和密集指导。麦基医生是 斯坦福大学的Redlich教授兼疼痛医学部主任。这款K24为DR提供了 Mackey为POR和指导提供了关键的保护时间，否则将花费在管理上 和临床责任。 麦基博士对这一K24应用程序的指导计划建立在他目前资助的Hear项目基础上，该项目名为： “高影响慢性疼痛的诊断和预后生物标记物：开发和验证”。慢性疼痛 代表着一场公共卫生危机，影响着1亿多美国人，耗资超过5000亿美元 每年一次。据估计，8%的美国成年人患有高冲击性慢性疼痛，或与 在六个月或更长时间内严重限制工作、社交和自我照顾活动。个体亚群 完全反应，不改变，甚至在疼痛处理后恶化。因此，健壮且经过验证 需要诊断和预后生物标记物来识别那些高影响的慢性疼痛患者，并确定 结果的轨迹(即，恢复与持续)。因此，我们的总体目标是 发现和验证肌肉骨骼高冲击性慢性疼痛的诊断和预后生物标志物。这 Goal需要全面、多维度的评估，具有集成的数据集和复杂的 计算分析流水线，以产生可靠和有效的诊断和预后生物标记物。对这件事 最后，我们组建了一个跨学科的研究和临床团队来实施Hear倡议。 麦基博士的指导计划包括对他的学员进行以下方面的培训：1)设计和实施疼痛研究 研究；2)准备科学论文和演讲；3)撰写成功的拨款申请；4) 负责任地进行研究；以及5)成功引导学术进程，实现科学 独立。这一指导计划将适用于他指导的K名受赠者和他作为 他的NIDA T32“疼痛和物质使用障碍的跨学科研究培训”的项目主任。 学员将以三种方式参与培训活动。第一种是通过直接参与 通过参与研究项目的各个方面，为R61/R33生物标记物项目创造条件。第二个是直通 研讨会、期刊俱乐部、会议和课程，扩展了我们的T32培训计划，重点是这一点 治愈生物标记物项目。第三个是通过学员主导的试点项目，利用母项目 资源和相关的多学科基础设施。资助的Hear项目，与 K24提供的额外指导时间将提供卓越的POR培训和指导 为我们现在和未来的一大批K获奖者、T32研究员和其他受训人员提供平台-并促进 他们转变为独立的、以患者为导向的疼痛研究人员。

The primary goal of this K24 application is to allow Sean Mackey, M.D., Ph.D., to build and expand on his high- quality and intensive mentorship of early-career investigators in patient-oriented research (POR). Dr. Mackey is the Redlich Professor and Chief, Division of Pain Medicine at Stanford University. This K24 provides Dr. Mackey with the critical protected time for POR and mentoring that would otherwise be spent on administrative and clinical responsibilities. Dr. Mackey's mentoring plan for this K24 application builds on his currently funded HEAL project entitled: “Diagnostic and prognostic biomarkers for high-impact chronic pain: Development and validation”. Chronic pain represents a public health crisis that affects more than 100 million Americans and costs over $500 billion annually. An estimated 8% of US adults suffer from high-impact chronic pain, or pain associated with substantially restricted work, social, and self-care activities for six or more months. Subgroups of individuals respond entirely, do not change, or even worsen following pain management. Thus, robust and validated diagnostic and prognostic biomarkers are needed to identify those with high-impact chronic pain and determine the trajectory of outcome (i.e., recovery versus persistence), respectively. Therefore, our overall goal is to discover and validate diagnostic and prognostic biomarkers for musculoskeletal high-impact chronic pain. This goal will require comprehensive, multidimensional assessments with an integrated dataset and a sophisticated computational analysis pipeline to yield reliable and validated diagnostic and prognostic biomarkers. To this end, we have assembled an interdisciplinary research and clinical team to implement the HEAL initiative. Dr. Mackey's mentoring plan includes training his mentees in: 1) designing and implementing pain research studies; 2) preparing scientific papers and presentations; 3) writing successful grant applications; 4) the responsible conduct of research; and 5) successful navigation of the academic process to achieve scientific independence. This mentoring plan will be applied to the K grantees he mentors and those he oversees as the Program Director for his NIDA T32 “Interdisciplinary Research Training in Pain and Substance Use Disorders.” The mentees will engage in the training activites in three manners. The first is through direct involvement in the parent R61/R33 biomarker project via participation in aspects of the research project. The second is through seminars, journal clubs, meetings, and coursework that expands on our T32 Training Program focusing on this HEAL biomarker project. The third is through trainee-led pilot projects that leverage the parent project resources and associated multidisciplinary infrastructure. The funded HEAL project, combined with the additional mentoring time provided by the K24, will provide an exceptional POR training and mentoring platform for our large group of current and future K awardees, T32 fellows, and other trainees – and facilitate their transition into independent patient-oriented pain researchers.